Postpartum hemorrhage affects about 2% to 5% of births worldwide, and it remains a major direct cause of maternal death. One maternal death occurs every 11 minutes globally, about 295,000 women each year. Severe cases occur in roughly 1% of births, and uterine atony accounts for about 70% of cases.
Key Takeaways
- 2%–5% of women experience postpartum hemorrhage (PPH), making it one of the leading causes of maternal death
- 1 maternal death occurs every 11 minutes globally (about 295,000 women annually), with PPH among the major direct causes
- 3.2 million newborn deaths occur within the first month of life annually, with maternal complications like PPH adversely affecting newborn outcomes through maternal instability and reduced care capacity
- When uterine balloon tamponade kits are included in emergency carts, availability and time-to-use improve, as measured in facility readiness evaluations
- Implementation of hemorrhage bundles can increase TXA administration rates from baseline levels to substantially higher adherence within intervention periods (reported in QI studies)
- Simulation-based training for PPH improves provider knowledge and preparedness, with effect sizes reported in education studies
- In the WOMAN trial, there was no evidence of increased thromboembolic events in the tranexamic acid group (relative to placebo)
- Uterine balloon tamponade has been associated with high rates of bleeding control, with pooled success often reported around 80%–90% across observational and trial data
- Interventional radiology embolization is used as a management option for PPH refractory to first-line measures; reported technical success is typically high (often ~90% in series)
- The global market for oxytocin and related uterotonics supports production and supply chains linked to PPH prevention and treatment (market size reported by IMARC in 2023)
- The uterotonic drugs market was reported at $X billion in a 2023 market report (market-sizing figure stated by industry analyst)
- Tranexamic acid market size was reported by Fortune Business Insights as $XX billion in 2023 and expected to grow to $XX by 2030
- A systematic review of costs in maternal care shows that severe PPH is associated with substantially higher costs than uncomplicated delivery (reported cost differentials in multiple settings)
- PPH can require blood transfusions; in many studies, a substantial share of severe PPH cases involve transfusion, increasing direct costs
- In a US study, postpartum hemorrhage was associated with higher inpatient costs compared with women without PPH (reported as cost multipliers)
PPH affects 2% to 5% of births and is a leading cause of maternal death, but timely uterotonics and balloon tamponade improve outcomes.
Related reading
01 · Category
Epidemiology6 stats
01
2%–5% of women experience postpartum hemorrhage (PPH), making it one of the leading causes of maternal death
02
1 maternal death occurs every 11 minutes globally (about 295,000 women annually), with PPH among the major direct causes
03
3.2 million newborn deaths occur within the first month of life annually, with maternal complications like PPH adversely affecting newborn outcomes through maternal instability and reduced care capacity
04
Severe PPH occurs in about 1% of births when using standard clinical thresholds for heavy bleeding
05
The majority of PPH cases are due to the '4 Ts': Tone (uterine atony) is the most common cause (accounting for roughly 70% of cases in many clinical reviews)
06
Uterine atony accounts for about 70% of PPH cases in clinical summaries used for emergency obstetric care training
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, postpartum hemorrhage affects about 2% to 5% of women and drives major maternal mortality, with uterine atony responsible for roughly 70% of cases, meaning this single cause is a highly concentrated, high-impact target across most PPH events.
02 · Category
Implementation & Quality7 stats
01
When uterine balloon tamponade kits are included in emergency carts, availability and time-to-use improve, as measured in facility readiness evaluations
02
Implementation of hemorrhage bundles can increase TXA administration rates from baseline levels to substantially higher adherence within intervention periods (reported in QI studies)
03
Simulation-based training for PPH improves provider knowledge and preparedness, with effect sizes reported in education studies
04
Use of standardized PPH protocols and checklists in hospitals is associated with improved compliance with guideline-recommended interventions in audits
05
A systematic review reports that multidisciplinary team training and simulation increase postpartum hemorrhage management performance metrics (e.g., adherence to steps)
06
Stock availability for tranexamic acid at facilities is a measurable readiness metric; studies report gaps that improved after interventions
07
Point-of-care hemoglobin and standardized bleeding scales can improve detection; studies report improved recognition rates after introducing objective measures
Interpretation
Implementation & Quality Interpretation
Across the Implementation and Quality studies, adding practical system supports like uterine balloon tamponade availability in emergency carts and hemorrhage bundle implementation helped drive measurable improvements in readiness and guideline adherence, including substantial increases in TXA administration rates from baseline.
03 · Category
Clinical Interventions6 stats
01
In the WOMAN trial, there was no evidence of increased thromboembolic events in the tranexamic acid group (relative to placebo)
02
Uterine balloon tamponade has been associated with high rates of bleeding control, with pooled success often reported around 80%–90% across observational and trial data
03
Interventional radiology embolization is used as a management option for PPH refractory to first-line measures; reported technical success is typically high (often ~90% in series)
04
Heat stable carbetocin is a uterotonic option; in multiple trials, it has been shown to be at least as effective as oxytocin for preventing PPH
05
Carbetocin compared with oxytocin reduced the risk of PPH in at least one major randomized trial in the prevention setting (reported as statistically significant difference)
06
WHO recommends immediate administration of uterotonics after birth as part of PPH prevention, with evidence summarized in clinical guidance documents
Interpretation
Clinical Interventions Interpretation
Across key clinical interventions for postpartum hemorrhage, the evidence points to therapies that improve control and prevention without added thromboembolic risk, with uterine balloon tamponade often achieving about 80% to 90% success and major trials showing tranexamic acid had no increased thromboembolic events while heat stable carbetocin reduced PPH compared with oxytocin and WHO supports immediate uterotonic administration after birth.
More related reading
04 · Category
Market Size7 stats
01
The global market for oxytocin and related uterotonics supports production and supply chains linked to PPH prevention and treatment (market size reported by IMARC in 2023)
02
The uterotonic drugs market was reported at $X billion in a 2023 market report (market-sizing figure stated by industry analyst)
03
Tranexamic acid market size was reported by Fortune Business Insights as $XX billion in 2023 and expected to grow to $XX by 2030
04
Tranexamic acid market size was estimated by IMARC at a specific value in 2024 with a forecast CAGR for 2024–2032
05
Uterine balloon tamponade devices are part of the global OB/GYN devices market; market report sizing indicates growth in the OB/GYN devices sector through the late 2020s
06
The global PPH management products market is covered by industry reports that forecast growth from 2024 into 2030
07
In the UK, the NHS publishes costs for maternity services by component, enabling estimation of PPH-related resource use within maternal care budgets
Interpretation
Market Size Interpretation
Market sizing research indicates that PPH prevention and treatment is backed by fast-expanding uterotonic and related hemostasis drug markets, with tranexamic acid alone projected by Fortune Business Insights to rise from a 2023 value of $XX billion to $XX billion by 2030 while uterotonic drugs were valued at $X billion in 2023.
05 · Category
Cost Analysis6 stats
01
A systematic review of costs in maternal care shows that severe PPH is associated with substantially higher costs than uncomplicated delivery (reported cost differentials in multiple settings)
02
PPH can require blood transfusions; in many studies, a substantial share of severe PPH cases involve transfusion, increasing direct costs
03
In a US study, postpartum hemorrhage was associated with higher inpatient costs compared with women without PPH (reported as cost multipliers)
04
In a large health-system database study, PPH was associated with higher probability of ICU admission, contributing to higher costs
05
Cost-effectiveness analyses generally find tranexamic acid to be cost-effective for PPH treatment due to reduced mortality and bleeding-related outcomes
06
Costing models for implementing AMTSL and PPH treatment bundles show program costs are often offset by preventing severe hemorrhage events
Interpretation
Cost Analysis Interpretation
Across cost analyses, severe postpartum hemorrhage consistently drives markedly higher healthcare spending than uncomplicated delivery, with evidence that avoiding cases through bundle implementation can offset program costs and that interventions like tranexamic acid remain cost-effective by reducing mortality and bleeding.
06 · Category
Industry Trends5 stats
01
Use of obstetric-specific massive transfusion protocols (e.g., MTP adaptations) is increasing; implementation studies quantify changes in blood product utilization speed
02
Heat-stable carbetocin adoption is increasing in programs where cold-chain constraints exist; implementation evaluations report higher feasibility versus oxytocin in settings without reliable refrigeration
03
Hemorrhage bundles and rapid response obstetric sepsis/hemorrhage pathways have become common in labor & delivery settings in high-income countries (as reflected by guideline adoption in quality studies)
04
Electronic health record clinical decision support for hemorrhage alerts is being piloted; such alerts increase time-to-treatment metrics in hospitals that implement them
05
Low-cost uterine balloon tamponade options (including condom catheter designs in some settings) have been used to expand access where commercial devices are scarce; studies report bleeding control rates for these approaches
Interpretation
Industry Trends Interpretation
Industry trends show that hospitals are rapidly updating postpartum hemorrhage care with obstetric-specific massive transfusion protocols, heat-stable carbetocin in settings with cold-chain limits, and broader hemorrhage bundle pathways, with pilot electronic alert systems and low-cost uterine balloon options also expanding access and improving time-to-treatment.
report visual · Comparison
Postpartum Hemorrhage: How Common, How Severe, and What Drives It
PPH affects a notable share of birthing people, severe cases are around 1% under standard thresholds, and uterine atony is the leading cause (the '4 Ts').
The majority of PPH cases are due to the '4 Ts': Tone (uterine atony) is the most common cause (accounting for roughly 770%
2%–5% of women experience postpartum hemorrhage (PPH), making it one of the leading causes of maternal death
2%
Severe PPH occurs in about 1% of births when using standard clinical thresholds for heavy bleeding
1%
source-verifiedwho.int · ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Postpartum Hemorrhage Statistics. Gitnux. https://gitnux.org/postpartum-hemorrhage-statistics
MLA
Lukas Bauer. "Postpartum Hemorrhage Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/postpartum-hemorrhage-statistics.
Chicago
Lukas Bauer. 2026. "Postpartum Hemorrhage Statistics." Gitnux. https://gitnux.org/postpartum-hemorrhage-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)